Latest news with #Nektar
Time Business News
09-07-2025
- Health
- Time Business News
Breakthrough Innovations Transforming Eczema Therapeutics
Eczema therapeutics refer to the range of medical remedies and interventions designed to manage and relieve symptoms of eczema, which is a chronic inflammatory skin condition characterized by itching, redness, dryness and irritation. Eczema therapeutics are rapidly expanding in the market, which is powered by factors such as pollution, lifestyle changes and increased chemical risk due to the increasing proliferation of eczema. Development of advanced treatments, especially dupilumab such as biologics that target specific immune routes, are more effective and improve patient results with personal care. Additionally, more awareness, better healthcare access, and strong infrastructure are further enhancing market development. Key Growth Drivers and Opportunities Rise of Telemedicine and Mobile Health Apps: Eczema therapeutics are promoting the market by improving access to care, especially for patients in remote or underserved areas by improving access to care. These digital tools enable virtual consultation, real-time skin monitoring and individual treatment adjustment without in-tradition visit. They also support symptoms tracking, education and adherence to treatment through reminder, encouraging frequent care. This change for digital health increases the results and engagement of the patient when opening new channels to manage and distribute driving market growth, driving market growth. Challenges Eczema therapeutics faces several borders, including high cost of advanced treatments such as biologics, which can restrict access to many patients. Additionally, variability and potential side effects in the patient's response to therapy face challenges for effective management. Limited awareness in low income areas, lack of long -term treatment, and the root cause of treatment, instead of treatment, also obstructs market growth on symptomatic relief. Regulatory obstacles and slow approval procedures for new drugs carry forward innovation and availability. Innovation and Expansion Nektar Therapeutics Reveals Groundbreaking Eczema Therapy Following 'New Biology' Discovery In June 2025, After the biotech firm met all of its targets in a mid-stage study of its eczema medication, Nektar Therapeutics (NKTR) launched by triple digits. In order to treat inflammatory skin diseases and other autoimmune problems, Nektar has developed a novel biology and capitalized on the potential of regulatory T cell proliferators as a significant therapeutic approach. Three subcutaneous injections of Nektar's medication, rezpegaldesleukin, were administered to research participants. According to the Eczema Area and Severity Index, or EASI, patients' symptoms improved by 53% to 61% after 16 weeks. In contrast, the placebo group saw an improvement of 31%. As the Eczema Trial Draws to a Close, Turn Therapeutics Launches its Last Round of Crowdfunding and Collaborates with Clear Street on Public Market Strategies In April 2025, In addition to the impending start of a controlled clinical trial assessing its flagship, non-steroidal topical platform in patients with moderate to severe eczema, Turn Therapeutics, a clinical-stage biotechnology company that is leading the way in next-generation topical therapies, announced the opening of its final crowdfund investment round. As part of a larger strategic funding plan to finance late-stage studies throughout its therapeutic pipeline, Turn has also enlisted Clear Street to evaluate routes to the public markets. Over the course of an eight-week treatment period, Turn's forthcoming trial will evaluate the therapeutic performance of its unique mix, tracking decreases in itching and disease severity. Inventive Sparks, Expanding Markets Prominent players working in the eczema therapeutics manufacturing include Sanofi, Regeneron Pharmaceuticals Inc., Almirall, SA, UCB SA, NT-MDT SI and others. Investing in R&D to create sequential and targeted treatment, expanding market access through partnerships and digital health platforms, raising awareness and starting education campaigns to increase diagnosis rates, and to increase strength and access through partnership with payments with payments and healthcare providers around the world are important development strategies for all important development strategies for all important development strategies. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Yahoo
25-06-2025
- Business
- Yahoo
Wainwright sets over $100 target for Nektar on ‘paradigm-shifting' data
H.C. Wainwright analyst Arthur He raised the firm's price target on Nektar (NKTR) to $120 from $6.50 and keeps a Buy rating on the shares. The company this morning announced positive results from the induction period of its ongoing Phase 2b REZOLVE-AD study evaluating rezpegaldesleukin in patients with moderate to-severe atopic dermatitis, the analyst tells investors in a research note. Citing the drug's 'highly differentiated mechanism of action' compared to currently approved therapies, H.C. Wainwright believes rezpeg 'has the potential to reshape the treatment landscape' for atopic dermatitis. The firm expects to see further improvement in efficacy in the next clinical data update when the 36-week maintenance data is expected to be reported in Q1 of 2026. Nektar says a 'paradigm-shifting' atopic dermatitis drug 'has arrived.' The stock in midday trading is up 134%, or $12.82, to $22.36. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on NKTR: Disclaimer & DisclosureReport an Issue Nektar price target raised to $120 from $6.50 at H.C. Wainwright Why Is Nektar Therapeutics Stock (NKTR) Up 110% Today? Nektar jumps 130% to $21.90 after atopic dermatitis study success Nektar Therapeutics Announces Positive Phase 2b Trial Results Nektar's rezpegaldesleukin meets endpoints in Phase 2b atopic dermatitis trial Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-06-2025
- Business
- Yahoo
Nektar Therapeutics Stock Doubles After Promising Eczema Drug Trial Results
Shares of Nektar Therapeutics doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a midstage study of its eczema treatment. The biotech firm said the global Phase 2b REZOLVE-AD study conducted in 393 patients with moderate-to-severe atopic dermatitis achieved successful results after three subcutaneous treatments of rezpegaldesleukin over 16 weeks. Nektar CEO Howard W. Robin said the study showed 'the promise of Tregs as an important potential therapeutic modality to treat inflammatory skin disorders and other autoimmune conditions.'Shares of Nektar Therapeutics (NKTR) doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a midstage study of its eczema treatment. It said the global Phase 2b REZOLVE-AD study conducted in 393 patients with moderate-to-severe atopic dermatitis achieved successful results after three subcutaneous treatments of rezpegaldesleukin over 16 weeks. "These data from REZOLVE-AD show a fast onset of both EASI response and itch relief within the first few doses of rezpegaldesleukin treatment, which are important metrics for physicians as they assess treatment options in atopic dermatitis," Jonathan Silverberg, professor of dermatology at the George Washington University School of Medicine and Health Sciences, said. He added that the drug didn't have an increased risk of conjunctivitis, oral herpes, or oral ulcers, as with some other approaches. Nektar CEO Howard W. Robin said the study showed 'the promise of Tregs as an important potential therapeutic modality to treat inflammatory skin disorders and other autoimmune conditions.' Tregs are T-regulatory cell therapies for autoimmune diseases. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-06-2025
- Business
- Yahoo
Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025
SAN FRANCISCO, June 23, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review top-line data from the 16-week induction period in the ongoing global Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for moderate-to-severe atopic dermatitis on Tuesday, June 24, 2025 at 8:15am ET / 5:15am PT. The data will be provided in a morning press release and presented during the webcast. Details on how to access the live webcast of the call will be available in the morning press release and on the Nektar website at A replay of the webcast will be available for at least 30 days following the event. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit and follow us on LinkedIn. For Investors: Corey Davis, PhDLifeSci Advisors212-915-2577cdavis@ For Media: Madelin HawtinLifeSci Communications603-714-2638mhawtin@ View original content to download multimedia: SOURCE Nektar Therapeutics
Reuters
24-06-2025
- Business
- Reuters
Nektar Therapeutics' experimental eczema drug meets main goals of mid-stage trial
June 24 (Reuters) - Nektar Therapeutics (NKTR.O), opens new tab said on Tuesday its experimental eczema drug had met the main goals of a mid-stage study. Shares of the company were halted in premarket trading.
